Form 4: Bioventus Director Martin Sutter Reports Significant Share Acquisition and New RSU Grant

Bioventus Inc. Director and 10% Owner Martin P. Sutter reported the acquisition of 26,493 Class A Common Stock shares through RSU vesting and a new grant of 32,282 Restricted Stock Units.

Summary

• Martin P. Sutter, a Director and 10% Owner of Bioventus Inc. (BVS), reported changes in his beneficial ownership.
• On June 2, 2025, Mr. Sutter acquired 26,493 shares of Class A Common Stock upon the vesting of Restricted Stock Units (RSUs).
• Following this transaction, Mr. Sutter directly owns 85,241 shares of Class A Common Stock.
• Additionally, Mr. Sutter indirectly owns 13,021,324 shares of Class A Common Stock through EW Healthcare Partners Acquisition Fund, L.P. and White Pine Medical, LLC.
• On June 3, 2025, Mr. Sutter was granted an additional 32,282 Restricted Stock Units.
• These newly granted RSUs are set to vest on the earlier of the day immediately preceding the Issuer's first Annual Meeting of Stockholders following the date of grant or the first anniversary of the date of grant, contingent on his continued service on the Board.

Sentiment

Score: 7

Explanation: The document reports routine insider transactions involving equity compensation (vesting and new grant of RSUs) for a director and 10% owner. This indicates continued alignment of interests and standard compensation practices, which is generally positive or neutral for the company's governance and stability, with no negative events like share sales.

Positives

• Acquisition of 26,493 shares of Class A Common Stock through RSU vesting indicates a conversion of contingent rights into direct equity ownership.
• Grant of an additional 32,282 Restricted Stock Units demonstrates continued compensation and alignment of interests between the director and the company's performance.

Future Outlook

The newly granted Restricted Stock Units (RSUs) for Martin P. Sutter are scheduled to vest on the earlier of the day immediately preceding the Issuer's first Annual Meeting of Stockholders following the grant date or the first anniversary of the grant date, contingent on his continued service on the Bioventus Inc. Board of Directors.

Related Party Transactions

• The indirect beneficial ownership of 13,021,324 shares is held through EW Healthcare Partners Acquisition Fund, L.P. and White Pine Medical, LLC, entities where Mr. Sutter is one of the managers of the general partner, indicating a related party relationship concerning share holdings.

Stakeholder Impact

• Shareholders: The vesting and grant of RSUs align the interests of a significant director and 10% owner with long-term shareholder value. The indirect ownership structure through investment funds provides insight into institutional holdings.

Next Steps

• The newly granted 32,282 Restricted Stock Units are expected to vest on the earlier of the day preceding the Issuer's first Annual Meeting of Stockholders following the grant date or the first anniversary of the grant date.

Key Dates

Recommendation

Keywords

Bioventus Inc., BVS, Martin P. Sutter, SEC Form 4, Insider Trading, Restricted Stock Units, RSU vesting, Share acquisition, Director ownership, 10% owner, Equity compensation, Corporate governance